Categories
Colon Cancer

How can we mitigate health inequalities in colorectal cancer? [Video]

Afsaneh Barzi, MD, PhD, City of Hope, Duarte, CA, describes strategies to reduce healthcare inequalities patients with colorectal cancer may face, including acknowledging these disparities, and cooperating with marginalized communities. Policies additionally need to reflect the fact that these patients are more likely to utilize the emergency room, as opposed to visiting a primary healthcare provider. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ

Categories
Colon Cancer

Highlights in gastric and colorectal cancer at ASCO GI 2023 [Video]

Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on his highlights presented at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including findings from the SPOTLIGHT trial (NCT03504397) of zolbetuximab in gastric and gastroesophageal junction (GEJ) cancer, as well as the SUNLIGHT trial (NCT04737187) of trifluridine and tipiracil with bevacizumab in metastatic colorectal cancer. Additional highlights include the use of regorafenib as second-line therapy in gastric cancer. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Colon Cancer

Practical considerations for genomic testing in colorectal cancer [Video]

Stacey Cohen, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on how genomic testing for molecular aberrations can influence treatment approaches in colorectal cancer. Liquid biopsies enable monitoring of multiple ctDNA mutations of varying frequencies, which can ultimately inform clinicians when a treatment regimen should be changed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ